Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Highlights from MyKE Myeloma 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.05.19
Views: 482
Rating:

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Prof Heinz Ludwig speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the main highlights from this year's meeting.

He discusses presentations about the relationship between MRD negativity and high-risk disease, imaging technologies used to diagnose multiple myeloma and the impact of neuropathy and bone disease.

Also, Prof Ludwig gives us an overview of the topics that were discussed in the second session, which included cardiac and renal implications that should be considered in multiple myeloma, the role of nurses in patient care and emerging immunotherapies for patients with multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation